Omecamtiv mecarbil is an effective and safe treatment for both men and women with heart failure with reduced ejection fraction (HFrEF), and sex-specific factors do not impact its benefits or risks. A study compared omecamtiv mecarbil with a placebo in patients with HFrEF and found that the rates of the primary endpoint of first HF event or CV death were lower in women compared to men. Women also had a decreased risk of CV death, HF event, and all-cause death. Women also had lower rates of serious adverse events compared to men. These findings have important implications for the management of HFrEF patients, especially women who are often undertreated and underrepresented in clinical trials.
Source link
Omecamtiv Mecarbil Effective for Men and Women With HFrEF
